MCID: PNT038
MIFTS: 46

Peanut Allergy

Categories: Immune diseases

Aliases & Classifications for Peanut Allergy

MalaCards integrated aliases for Peanut Allergy:

Name: Peanut Allergy 12 15
Peanut Allergic Reaction 12 17
Allergy to Peanuts 12 70
Peanut Hypersensitivity 44
Allergies Peanut 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4378
MeSH 44 D021183
SNOMED-CT 67 91935009
UMLS 70 C0559470

Summaries for Peanut Allergy

Disease Ontology : 12 A legume allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms.

MalaCards based summary : Peanut Allergy, also known as peanut allergic reaction, is related to pollen allergy and exanthem. An important gene associated with Peanut Allergy is IGHE (Immunoglobulin Heavy Constant Epsilon), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and b cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies, with... more...

Related Diseases for Peanut Allergy

Diseases related to Peanut Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 403)
# Related Disease Score Top Affiliating Genes
1 pollen allergy 30.6 IL5 IL13 IGHE
2 exanthem 30.5 IL10 IFNG CCR6
3 food allergy 30.3 IL5 IL4 IL13 IL10 IGHE IFNG
4 urticaria 30.2 IL5 IL4 IL13 IL10 IGHE
5 cytokine deficiency 30.0 IL9 IL5 IL13
6 rhinitis 29.9 IL9 IL5 IL4 IL13 IL10 IGHE
7 acute asthma 29.9 IL5 IL4
8 severe combined immunodeficiency 29.7 IL9 IL4 IL13 IL10 IFNG
9 disease by infectious agent 29.6 IL4 IL10 IFNG CCR6
10 allergic rhinitis 29.6 IL9 IL5 IL4 IL13 IL10 IGHE
11 eosinophilic gastroenteritis 29.6 IL5 IL4 CCR6
12 nut allergy 29.6 IL5 IL4 IL13 IGHE FLG CCR6
13 gastroenteritis 29.6 IL5 IL4 IL10 IFNG
14 ige responsiveness, atopic 29.5 IL5 IL4 IL13 IL10 IGHE IFNG
15 type 1 diabetes mellitus 29.5 IL4 IL10 IFNG HLA-DRB1 HLA-DQB1 CXCL10
16 esophagitis 29.4 IL5 IL4 IL13 IL10 FLG EMSY
17 sarcoidosis 1 29.4 IL9 IL13 IFNG HLA-DRB1 HLA-DQB1 CXCL10
18 esophagitis, eosinophilic, 1 29.3 IL9 IL5 IL4 IL13 FLG CCR6
19 hypereosinophilic syndrome 29.2 IL9 IL5 IL4 IL13 IGHE IFNG
20 dermatitis 29.2 IL5 IL4 IL13 IL10 IGHE IFNG
21 alopecia areata 29.1 IL4 IL13 IL10 IFNG HLA-DRB1 HLA-DQB1
22 respiratory failure 29.1 IL5 IL13 IL10 CXCL10 CCR6 CCL17
23 immune deficiency disease 29.1 IL4 IL13 IL10 IFNG HLA-DQB1 CXCL10
24 milk allergy 29.1 IL9 IL5 IL4 IL13 IL10 IGHE
25 schistosomiasis 29.0 IL9 IL5 IL4 IL13 IL10 IGHE
26 egg allergy 29.0 PEDS1 IL5 IL4 IL13 IL10 IGHE
27 allergic asthma 28.8 IL9 IL5 IL4 IL13 IL10 IGHE
28 combined immunodeficiency 28.6 MALT1 IL9 IL5 IL4 IL13 IL10
29 allergic disease 28.5 IL9 IL5 IL4 IL13 IL10 IGHE
30 dermatitis, atopic 28.4 IL9 IL5 IL4 IL13 IL10 IGHE
31 fruit allergy 28.2 PEDS1 LCOR IL5 IL4 IL13 IL10
32 contact dermatitis 28.1 IL9 IL5 IL4 IL10 IFNG FLG
33 asthma 27.6 IL9 IL5 IL4 IL13 IL10 IGHE
34 cholera 10.5
35 beryllium disease 10.5 HLA-DRB1 HLA-DQB1
36 limbic encephalitis with lgi1 antibodies 10.5 HLA-DRB1 HLA-DQB1
37 autoimmune polyglandular syndrome type 3 10.4 HLA-DRB1 HLA-DQB1
38 idiopathic hypersomnia 10.4 HLA-DRB1 HLA-DQB1
39 hypersomnia 10.4 HLA-DRB1 HLA-DQB1
40 narcolepsy 2 10.4 HLA-DRB1 HLA-DQB1
41 htlv-1 associated myelopathy/tropical spastic paraparesis 10.4 HLA-DRB1 HLA-DQB1
42 latent autoimmune diabetes in adults 10.4 HLA-DRB1 HLA-DQB1
43 juvenile myasthenia gravis 10.4 IL10 HLA-DRB1
44 exercise-induced anaphylaxis 10.4 IGHE FLG
45 primary adrenal insufficiency 10.4 HLA-DRB1 HLA-DQB1
46 recurrent respiratory papillomatosis 10.4 HLA-DRB1 HLA-DQB1
47 childhood-onset asthma 10.4 IL13 IGHE
48 staphylococcal toxic shock syndrome 10.4 IGHE IFNG
49 apple allergy 10.4 HLA-DRB1 HLA-DQB1
50 occupational asthma 10.4 IGHE HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Peanut Allergy:



Diseases related to Peanut Allergy

Symptoms & Phenotypes for Peanut Allergy

MGI Mouse Phenotypes related to Peanut Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.77 CCL17 CCR6 CD14 CXCL10 HLA-DQB1 IFNG
2 immune system MP:0005387 9.44 CCL17 CCL22 CCR6 CD14 CXCL10 HLA-DQB1

Drugs & Therapeutics for Peanut Allergy

Drugs for Peanut Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 3 242138-07-4
2 Antibodies Phase 3
3 Immunoglobulins Phase 3
4 Immunoglobulins, Intravenous Phase 3
5 Immunoglobulin E Phase 3
6 Vaccines Phase 3
7 Anti-Allergic Agents Phase 3
8 Respiratory System Agents Phase 3
9 Anti-Asthmatic Agents Phase 3
10 Immunologic Factors Phase 3
11 Antibodies, Monoclonal Phase 3
12
Ketotifen Approved Phase 2 34580-14-8, 34580-13-7 3827
13
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
14
Glycerol Approved, Investigational Phase 1, Phase 2 56-81-5 753
15
Vancomycin Approved Phase 1, Phase 2 1404-90-6 14969 441141
16
Polyestradiol phosphate Approved Phase 2 28014-46-2
17
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
18
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
19
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
20
Trichostatin A Experimental Phase 1, Phase 2 58880-19-6
21 Histamine Antagonists Phase 2
22 Dermatologic Agents Phase 2
23 Histamine H1 Antagonists Phase 2
24
Histamine Phosphate Phase 2 51-74-1 65513
25 Pharmaceutical Solutions Phase 2
26 Protective Agents Phase 1, Phase 2
27 Anti-Infective Agents Phase 1, Phase 2
28 Immune Sera Phase 2
29 Contraceptive Agents Phase 2
30 Estradiol 3-benzoate Phase 2
31 Hormone Antagonists Phase 2
32 Estradiol 17 beta-cypionate Phase 2
33 Hormones Phase 2
34
Medroxyprogesterone Phase 2 520-85-4 10631
35 Estrogens Phase 2
36 Progestins Phase 2
37
Fluoxymesterone Approved, Illicit Phase 1 76-43-7 6446
38
Phenol Approved, Experimental Phase 1 108-95-2 996
39 Anti-Bacterial Agents Phase 1
40 Antibiotics, Antitubercular Phase 1
41
Epinephrine Approved, Vet_approved 51-43-4 5816
42
Racepinephrine Approved 329-65-7 838
43
Nitric Oxide Approved 10102-43-9 145068
44
tannic acid Approved 1401-55-4
45
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
46 Neurotransmitter Agents
47 Epinephryl borate
48 Vasodilator Agents
49 Antioxidants
50 Bronchodilator Agents

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Completed NCT01966640 Phase 4
2 Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers Unknown status NCT02046083 Phase 2, Phase 3 arachid
3 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study Completed NCT02993107 Phase 3
4 Safety Study of Viaskin Peanut to Treat Peanut Allergy Completed NCT02916446 Phase 3
5 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Completed NCT02635776 Phase 3
6 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years Completed NCT03126227 Phase 3
7 AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS) Completed NCT03201003 Phase 3
8 A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children Completed NCT02636699 Phase 3
9 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE) Completed NCT03337542 Phase 3
10 Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11) Recruiting NCT03881696 Phase 3 Omalizumab;Placebo for Omalizumab;Multi-Allergen Oral Immunotherapy;Placebo for Multi-Allergen Oral Immunotherapy
11 Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON) Recruiting NCT03736447 Phase 3
12 A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age. Recruiting NCT03211247 Phase 3
13 Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut Active, not recruiting NCT03013517 Phase 3 Viaskin Peanut 250µg
14 EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children Enrolling by invitation NCT03859700 Phase 3
15 A Multicenter, Open-label, Long-term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study Enrolling by invitation NCT03292484 Phase 3
16 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study Terminated NCT03703791 Phase 3
17 The Effect of Extrinsic Factors on Food Allergy Unknown status NCT01429896 Phase 2
18 A Prospective, Randomized, Case Controlled, Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization in Children With Peanut Allergies. Unknown status NCT01625715 Phase 2 Ketotifen
19 Clinical Desensitization and Tolerance Following Peanut Oral Immunotherapy and Subsequent Allergen Avoidance Unknown status NCT01750879 Phase 1, Phase 2 Peanut Flour;Oat Flour
20 Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair Unknown status NCT02402231 Phase 2 Omalizumab
21 Xolair Enhances Oral Desensitization in Peanut Allergic Patients Completed NCT01290913 Phase 1, Phase 2 Omalizumab
22 Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD) Completed NCT00329784 Phase 2
23 Oral Immunotherapy for Peanut Allergy- Peanut Oral Immunotherapy (PnOIT3) Completed NCT00815035 Phase 2 Peanut OIT;Placebo
24 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed NCT01084174 Phase 1, Phase 2 Peanut powder;Peanut extract;Placebo extract;Placebo powder
25 Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6) Completed NCT01904604 Phase 2
26 Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy} Completed NCT01373242 Phase 1, Phase 2 Liquid peanut extract (Peanut SLIT)
27 Peanut OIT & Anti-IgE: Peanut Oral Immunotherapy and Anti-IgE Treatment for Peanut Allergy {NIH R21 Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies} Completed NCT00932282 Phase 1, Phase 2 Peanut Oral Immunotherapy;Omalizumab
28 Oral Immunotherapy for Peanut Allergy (2nd Generation PMIT Collaboration With Arkansas Children's) Completed NCT00597675 Phase 2
29 Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract Completed NCT00580606 Phase 1, Phase 2 Glycerinated peanut allergenic extract;Placebo for peanut extract (glycerin)
30 A Double-blind, Placebo-controlled, Randomized Trial to Study the Viaskin Peanut's Efficacy and Safety for Treating Peanut Allergy in Children and Adults. Completed NCT01675882 Phase 2
31 Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects Completed NCT02103270 Phase 2 Peanut Protein 4,000mg;Oat Flour;Peanut Protein 300 mg
32 Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy Completed NCT02920021 Phase 2 ANB020;Placebo
33 ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut Completed NCT01197053 Phase 2
34 Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut Completed NCT01955109 Phase 2
35 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study Completed NCT02198664 Phase 2
36 Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy Completed NCT01987817 Phase 2
37 A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS) Completed NCT00382148 Phase 2 omalizumab
38 Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD) Completed NCT01867671 Phase 2
39 Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children Completed NCT02304991 Phase 2 Liquid Peanut Extract;Placebo Glycerin SLIT
40 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study; Grant "Optimizing Tolerance Induction in Peanut Allergy: The DEVIL Study" Completed NCT00932828 Phase 2 Peanut oral immunotherapy
41 Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults Completed NCT00949078 Phase 2 omalizumab
42 VE416 and Low-dose Peanut Oral Immunotherapy for Treatment of Persistent Peanut Allergy Recruiting NCT03936998 Phase 1, Phase 2
43 Prospective Study to Identify Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in Patients With Elevated Total Serum IgE Levels and Atopic Dermatitis Recruiting NCT03835767 Phase 2
44 A Multicenter Double-blind, Randomized, Placebocontrolled Phase I/II Study to Determine the Safety, Tolerability, Potential Efficacy and Dose Finding of INP20, an Oral Formulation for Treatment of Immunotherapy in Peanut-allergic Patients Recruiting NCT04163562 Phase 1, Phase 2 INP20;Placebo
45 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women Recruiting NCT03018366 Phase 2 17beta Estradiol;Transdermal placebo patch;Progesterone;Placebo Pill
46 Challenging to Food With Escalating Thresholds for Reducing Food Allergy Recruiting NCT03907397 Phase 2
47 Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes Recruiting NCT03679676 Phase 2 Omalizumab;Dupilumab
48 A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Active, not recruiting NCT03793608 Phase 2 Dupilumab
49 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Active, not recruiting NCT03682770 Phase 2 Dupilumab;Placebo matching dupilumab;AR101
50 Phase 2 Study of Omalizumab in Oral Peanut Desensitization Active, not recruiting NCT01781637 Phase 1, Phase 2 Omalizumab;placebo

Search NIH Clinical Center for Peanut Allergy

Cochrane evidence based reviews: peanut hypersensitivity

Genetic Tests for Peanut Allergy

Anatomical Context for Peanut Allergy

MalaCards organs/tissues related to Peanut Allergy:

40
Skin, T Cells, B Cells, Bone Marrow, Pancreas, Neutrophil

Publications for Peanut Allergy

Articles related to Peanut Allergy:

(show top 50) (show all 1247)
# Title Authors PMID Year
1
Lupin allergy in peanut-allergic children and teenagers. 61 54
18028245 2008
2
Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. 61 54
18234310 2008
3
Early clinical predictors of remission of peanut allergy in children. 54 61
18234313 2008
4
Alleviating peanut allergy using genetic engineering: the silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity. 54 61
17784907 2008
5
Lupine allergy: not simply cross-reactivity with peanut or soy. 54 61
17637469 2007
6
Towards immunotherapy for peanut allergy. 54 61
16264338 2005
7
Clinical pearls and pitfalls: peanut allergy. 54 61
15971474 2005
8
Peanut allergy: recurrence and its management. 61 54
15536431 2004
9
Isoforms of the major peanut allergen Ara h 2: IgE binding in children with peanut allergy. 61 54
15345908 2004
10
Specific immunoglobulin E antibodies to peanut over time in relation to peanut intake, symptoms and age. 61 54
15482520 2004
11
Serological characteristics of peanut allergy in children. 61 54
14616104 2003
12
Relevance of casual contact with peanut butter in children with peanut allergy. 54 61
12847496 2003
13
Measurement of peptide-specific IgE as an additional tool in identifying patients with clinical reactivity to peanuts. 54 61
12847500 2003
14
Patients with anaphylaxis to pea can have peanut allergy caused by cross-reactive IgE to vicilin (Ara h 1). 61 54
12589366 2003
15
Association of end-product adducts with increased IgE binding of roasted peanuts. 61 54
11513688 2001
16
Specific IgE antibodies to peanut in western Sweden--has the occurrence of peanut allergy increased without an increase in consumption? 54 61
11421907 2001
17
The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. 61 54
11113829 2000
18
The effects of roasting on the allergenic properties of peanut proteins. 54 61
11031348 2000
19
A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. 61 54
10887318 2000
20
Heat-induced conformational changes of Ara h 1, a major peanut allergen, do not affect its allergenic properties. 61 54
9988715 1999
21
Immunogenetic analysis of the heavy chain variable regions of IgE from patients allergic to peanuts. 54 61
9525457 1998
22
Poor biologic activity of cross-reactive IgE directed to carbohydrate determinants of glycoproteins. 61 54
9314344 1997
23
Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity. 54 61
7560062 1995
24
Adverse reaction to lupine-fortified pasta. 61 54
8064069 1994
25
The production of interferon-gamma in response to a major peanut allergy, Ara h II correlates with serum levels of IgE anti-Ara h II. 61 54
8308186 1994
26
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States. 61
33470880 2021
27
Treatment of Peanut Allergy. 61
33795470 2021
28
Peanuts in the air - clinical and experimental studies. 61
33548082 2021
29
The Cost-Effectiveness of Pre-school Peanut Oral Immunotherapy in the Real World Setting. 61
33744474 2021
30
Bayesian hierarchical evaluation of dose-response for peanut allergy in clinical trial screening. 61
33722597 2021
31
EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update). 61
33710678 2021
32
Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research. 61
33290772 2021
33
Targeted DNA methylation profiling reveals epigenetic signatures in peanut allergy. 61
33571165 2021
34
Peanut Allergen Powder-dnfp: A Novel Oral Immunotherapy to Mitigate Peanut Allergy. 61
32718178 2021
35
Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy. 61
33483153 2021
36
Delayed symptoms and orthostatic intolerance following peanut challenge. 61
33715235 2021
37
Ara h 2-specific IgE is superior to whole peanut extract-based serology or skin prick test for diagnosis of peanut allergy in infancy. 61
33483152 2021
38
Peanut diversity and specific activity are the dominant IgE characteristics for effector cell activation in children. 61
33675817 2021
39
Emerging developments in the forefront of peanut oral immunotherapy. 61
33769315 2021
40
Effect of roasted peanut allergen Ara h 3 protein on the sensitization of Caco-2 cells. 61
33650104 2021
41
IgE-reactivity profiles to allergen molecules in Russian children with and without symptoms of allergy revealed by micro-array analysis. 61
32869350 2021
42
The year's new drugs and biologics 2020. 61
33656016 2021
43
Prevalence and characteristics of peanut allergy in US adults. 61
33579526 2021
44
Altered immune cell profiles and impaired CD4 T-cell activation in single and multi-food allergic adolescents. 61
33626189 2021
45
Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis. 61
33571537 2021
46
Food allergy history and reaction to propofol administration in a large pediatric population. 61
33529424 2021
47
The Peanut Allergy Burden Study: Impact on the quality of life of patients and caregivers. 61
33664934 2021
48
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. 61
33259921 2021
49
Oral immunotherapy: The answer to peanut allergy? 61
33526464 2021
50
Evolution of epitope-specific IgE and IgG4 antibodies in children enrolled in the LEAP trial. 61
33592205 2021

Variations for Peanut Allergy

Expression for Peanut Allergy

Search GEO for disease gene expression data for Peanut Allergy.

Pathways for Peanut Allergy

Pathways related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 MALT1 IL9 IL5 IL4 IL13 IL10
2
Show member pathways
13.8 IL9 IL5 IL4 IL13 IL10 CXCL10
3
Show member pathways
13.69 IL9 IL5 IL4 IL13 IL10 IFNG
4
Show member pathways
13.52 IL9 IL5 IL4 IL13 IL10 IFNG
5
Show member pathways
13.43 IL9 IL5 IL4 IL13 IL10 CXCL10
6
Show member pathways
13.32 IL9 IL5 IL4 IL13 IL10 CXCL10
7
Show member pathways
13.28 IL9 IL5 IL4 IL13 IL10 IGHE
8
Show member pathways
12.82 IL9 IL5 IL4 IL13 IL10 IFNG
9
Show member pathways
12.66 MALT1 IL4 IL10 IGHE IFNG HLA-DRB1
10
Show member pathways
12.64 MALT1 IL9 IL5 IL4 IL10 IFNG
11
Show member pathways
12.61 IL5 IL4 IL13 IL10 IFNG HLA-DRB1
12 12.57 MALT1 IL4 IL10 IFNG CXCL10
13
Show member pathways
12.46 IL9 IL5 IL4 IL13 IL10 IFNG
14
Show member pathways
12.37 IL10 CXCL10 CCR6 CCL22 CCL17
15
Show member pathways
12.35 IL5 IL4 IL13 IFNG CXCL10 CCL17
16
Show member pathways
12.3 IL4 IL10 IFNG HLA-DRB1 HLA-DQB1
17
Show member pathways
12.3 IL9 IL5 IL4 IL13 IL10 IFNG
18 12.23 MALT1 IL10 IFNG HLA-DRB1 HLA-DQB1 CD14
19
Show member pathways
12.2 MALT1 IL10 CCL22 CCL17
20
Show member pathways
12.18 IL4 IFNG CXCL10 CD14
21 12.04 IL5 IL4 IL10 IFNG CD14
22 12.02 IL4 IL13 IL10 IGHE CCL22
23 11.94 IL5 IL4 HLA-DRB1 HLA-DQB1 CD14
24 11.85 IL5 IL4 IL13 IFNG
25 11.84 IL10 HLA-DRB1 HLA-DQB1
26 11.83 IFNG HLA-DRB1 HLA-DQB1
27 11.74 IL5 IL4 IL10 CCR6
28
Show member pathways
11.73 IL5 IL4 IFNG
29 11.71 IL10 IFNG CD14
30 11.7 IL9 IL5 IL4 IL13 IL10 IFNG
31 11.65 IL5 IL4 IL10 IGHE CCL17
32 11.64 IL5 IL4 IL13
33 11.49 IL4 IL13 IL10 CXCL10 CCL22
34 11.35 IL5 IL4 IFNG
35 11.27 IL13 IFNG HLA-DRB1
36 11.22 IL9 IL5 IL4 IL13 IFNG
37 11.1 IL5 IL4 IL13 IL10 IFNG HLA-DRB1
38 11.02 IL9 IL5 IL4 IL13 IL10 CXCL10
39 10.89 IL9 IL5 IL4 IL13 IL10 IFNG
40 10.85 IL9 IL5 IL4 IL13 IL10 IFNG
41 10.75 IL9 IL5 IL4 IL13

GO Terms for Peanut Allergy

Cellular components related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 IL9 IL5 IL4 IL13 IL10 IGHE
2 external side of plasma membrane GO:0009897 9.63 IL13 IGHE HLA-DRB1 CXCL10 CD14 CCR6
3 extracellular space GO:0005615 9.4 IL9 IL5 IL4 IL13 IL10 IFNG

Biological processes related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.04 IL9 IL5 IL4 IFNG CXCL10
2 response to lipopolysaccharide GO:0032496 9.88 IL13 IL10 CXCL10 CD14
3 cellular response to lipopolysaccharide GO:0071222 9.87 MALT1 IL10 CXCL10 CD14
4 chemotaxis GO:0006935 9.83 CXCL10 CCR6 CCL22 CCL17
5 neutrophil chemotaxis GO:0030593 9.79 CXCL10 CCL22 CCL17
6 interferon-gamma-mediated signaling pathway GO:0060333 9.79 IFNG HLA-DRB1 HLA-DQB1
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IL4 IL13 IFNG
8 positive regulation of cytokine production GO:0001819 9.77 IL10 IFNG CD14
9 inflammatory response GO:0006954 9.7 IL9 IL5 IL13 CXCL10 CD14 CCL22
10 positive regulation of B cell proliferation GO:0030890 9.69 IL5 IL4 IL13
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 IL4 IL13 IL10
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.64 HLA-DRB1 HLA-DQB1
13 positive regulation of signaling receptor activity GO:2000273 9.63 IL10 IFNG
14 macrophage activation GO:0042116 9.63 IL4 IL13
15 response to molecule of bacterial origin GO:0002237 9.62 IL10 CD14
16 chemokine-mediated signaling pathway GO:0070098 9.62 CXCL10 CCR6 CCL22 CCL17
17 positive regulation of mast cell degranulation GO:0043306 9.6 IL4 IL13
18 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.58 HLA-DRB1 HLA-DQB1
19 microglial cell activation GO:0001774 9.58 IL4 IL13 IFNG
20 positive regulation of cellular respiration GO:1901857 9.56 IL4 IFNG
21 neuroinflammatory response GO:0150076 9.55 IL4 IFNG
22 type 2 immune response GO:0042092 9.54 IL4 IL10
23 positive regulation of immunoglobulin production GO:0002639 9.54 IL5 IL13 IL10
24 cytokine-mediated signaling pathway GO:0019221 9.5 IL5 IL4 IL13 IL10 IGHE CXCL10
25 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL4 IL13
26 regulation of isotype switching GO:0045191 9.46 IL4 IL10
27 immune response GO:0006955 9.44 IL9 IL5 IL4 IL13 IL10 IGHE
28 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.43 HLA-DRB1 HLA-DQB1
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IL4 IL10 IFNG

Molecular functions related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL9 IL5 IL4 IL10
2 chemokine activity GO:0008009 9.43 CXCL10 CCL22 CCL17
3 MHC class II receptor activity GO:0032395 9.32 HLA-DRB1 HLA-DQB1
4 cytokine activity GO:0005125 9.28 IL9 IL5 IL4 IL13 IL10 IFNG
5 cytokine receptor binding GO:0005126 9.13 IL9 IL4 IL13

Sources for Peanut Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....